Dianne Leach
Physical Medicine & Rehabilitation · Indianapolis, INNPI 1346400942
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 30.9% of the total. Reporting peaked in 2023 at $789 and has fallen 83.0% since, to $134 in 2025.
Across 74 payments — averaging $31.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$712
- ANI Pharmaceuticals, Inc.$342
- Axsome Therapeutics, Inc.$243
- Biohaven Pharmaceutical Holding Company Ltd.$125
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$112
- Collegium Pharmaceutical, Inc.$111
- plus $662 from 16 others
What the payments were for
- Food & beverage$2,308100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 19 | $712 |
| ANI Pharmaceuticals, Inc. | 9 | $342 |
| Axsome Therapeutics, Inc. | 4 | $243 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $125 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $112 |
| Collegium Pharmaceutical, Inc. | 6 | $111 |
| AbbVie | 4 | $102 |
| Protega Pharmaceutials Inc | 2 | $101 |
| Orexo US, Inc. | 6 | $94 |
| Merck | 4 | $73 |
| Indivior Inc. | 2 | $46 |
| Novo Nordisk | 3 | $41 |
| Pfizer | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Redhill Biopharma Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$377
- NURTEC ODT$125
- SUNOSI$121
- Austedo XR$118
- PURIFIED CORTROPHIN GEL$117
How this compares
$2,308 in reported general payments places this provider in the 80th percentile of 140 physical medicine & rehabilitation providers in Indiana.
See all physical medicine & rehabilitation providers in Indiana →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 35 | $35,322 |
| Xtampza ErOxycodone Myristate | 18 | $17,420 |
| BelbucaBuprenorphine Hcl | 16 | $15,727 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 65 | $12,250 |
| Oxycodone Hcl | 276 | $9,231 |
| MovantikNaloxegol Oxalate | 15 | $7,762 |
| Fentanyl | 35 | $7,194 |
| Buprenorphine | 11 | $5,145 |
| Morphine Sulfate ErMorphine Sulfate | 116 | $4,410 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 93 | $3,489 |
| Morphine Sulfate | 69 | $3,012 |
| Buprenorphine Hcl | 20 | $2,255 |
| Naproxen | 35 | $2,214 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 63 | $1,909 |
| Pregabalin | 46 | $1,572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $111 | $33,14734 claims |
| Redhill Biopharma Inc.Movantik | $20 | $7,76215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 140 physical medicine & rehabilitation providers in Indiana.
Other physical medicine & rehabilitation in Indianapolis
- Shashank DaveIndianapolis$198K
- Sachin MehtaIndianapolis$60K
- Anthony MimmsIndianapolis$10K
- Flora HammondIndianapolis$9K
- Eric AitkenIndianapolis$5K
- Kyle MazellanIndianapolis$2K
- Abhishek ReddyIndianapolis$2K
- Raghu MaddelaIndianapolis$2K
- Anand NavarasalaIndianapolis$2K
- Shiva GangadharIndianapolis$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.